Key result
A 10% increase in serum MCP-1 concentration predicted a 25% increase in the probability of a poor neurological outcome following aneurysmal subarachnoid hemorrhage.
Why the study?
Does MCP-1 concentration in serum and CSF predict poor neurological outcome and vasospasm in patients with aneurysmal subarachnoid hemorrhage?
Population
77 patients with aneurysmal subarachnoid hemorrhage and 14 controls undergoing clipping of unruptured…
Comparison
Measurement of Monocyte chemoattractant… vs Control group of patients undergoing clipping of…
Design
Cohort, Neurological outcome evaluated by an independent neurologist…
Follow-up
14 days or discharge
Authors
Loading...
May support MCP-1 for prognostication after aneurysmal subarachnoid hemorrhage; leaves open prospective validation before clinical adoption.
Observational (n=91)
No
Does MCP-1 concentration in serum and CSF predict poor neurological outcome and vasospasm in patients with aneurysmal subarachnoid hemorrhage?
Effect estimate: 25% increase in probability of poor outcome per 10% increase in serum MCP-1
Elevated MCP-1 levels in serum and CSF may serve as biomarkers for poor neurological outcome and vasospasm, respectively, following aneurysmal subarachnoid hemorrhage.
Kim et al. (2008) conducted an observational in Aneurysmal subarachnoid hemorrhage (ASAH) (n=91). Serum and cerebrospinal fluid MCP-1 concentrations vs. Lower MCP-1 concentrations or unruptured aneurysm controls was evaluated on Poor neurological outcome (modified Rankin Scale 4-6) at 14 days or discharge (25% increase in probability of poor outcome per 10% increase in serum MCP-1). A 10% increase in serum MCP-1 concentration predicted a 25% increase in the probability of a poor neurological outcome following aneurysmal subarachnoid hemorrhage.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: